Thus, the mainstay of treatment for metastatic PCa remains androgen-deprivation therapy (ADT), which inhibits AR activity, suppresses AR target genes, and elicits clinical remission that will last a couple of years [4,5]. Here, AR is linked to posterior cortical atrophy.